Pancreas · 2011 · 52 citations · 22 references
MedicinePharmacologyPharmacotherapyClinical PharmacologyPharmacovigilancePrecision MedicinePancreatic DiseasesPancreatic PathologyPancreatic SurgeryAntisecretory TherapyBiliary PancreatitisLow-risk Patient PopulationsManagement Of High-risk PatientsNafamostat MesylatePancreatitis Risk
OBJECTIVE: Infusion of the protease inhibitor nafamostat mesilate (20 mg) effectively prevents post-ERCP pancreatitis, but only in low-risk groups. This study was performed to evaluate the use of high-dose nafamostat mesilate (50 mg) for prevention of post-ERCP pancreatitis (PEP), especially in high-risk groups. METHODS: A total of 608 patients who underwent ERCP were included; 13 patients were excluded. Patients were divided into 3 groups: controls (group A), infusion with 20 mg of nafamostat mesilate (group B), or infusion with 50 mg of nafamostat mesilate (group C). The incidence of PEP was analyzed. RESULTS: The overall incidence of acute pancreatitis was 7.4% (44/595). There was a significant difference in the incidence of PEP with or without nafamostat mesilate (13.0% vs 4.0% and 5.1%, respectively; P < 0.0001). Subgroup analysis showed that in low-risk patients, the rate of PEP was significantly different with nafamostat (11.9% vs 2.7% and 4.0%, respectively; P = 0.007). In high-risk patients, the rate of PEP was not significantly different among treatment groups (14.6% vs 5.9% vs 6.9%, respectively; P = 0.108). CONCLUSIONS: Nafamostat mesilate prophylaxis (20 or 50 mg) is effective in preventing post-ERCP pancreatitis. However, the preventive effect of high-dose nafamostat mesilate (50 mg) is not significant in high-risk patients.
22
Complications of Diagnostic and Therapeutic Ercp: A Prospective Multicenter Study
E. Masci, G Toti, A. Mariani et al. · The American Journal of Gastroenterology · 2001 · 915 citations
Medicine, Clinical Sciences, Surgery +16